Clinical trials
Immunogenicity clinical trials
Below are recruiting immunogenicity clinical trials, each written for real people, not researchers. We’re tracking 150 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07245927Recruiting
Staphylokinase for massive pulmonary embolism with shock
This trial tests a single injection of a clot-busting drug called staphylokinase for people with a massive pulmonary embolism that is causing shock or very low blood pressure. It aims to see how well the drug works in this emergency situation.
BelgorodAges 18 years+ - NCT07783243Recruiting
Leishmaniasis vaccine response study in Ethiopia
This study tests how your immune system responds to parts of a potential vaccine for leishmaniasis. Doctors will take small blood or skin samples to see if your body's cells react to these vaccine pieces, which could help design a better vaccine in the future.
Addis AbabaAges 18–65 - NCT07390474RecruitingPhase 1
HIV vaccine safety and immune response study for healthy adults
This study tests two experimental mRNA-based HIV vaccines to see if they are safe and create an immune response. It is for healthy adults aged 18 to 55 who do not have HIV.
Atlanta, GeorgiaAges 18–55 - NCT07324837RecruitingPhase 3
Study of a clot-busting drug for stroke up to 24 hours later
This trial tests a single dose of a new clot-dissolving medicine for people who had a stroke 4.5 to 24 hours ago. It may help if you cannot have standard treatments like a clot-removal procedure or other clot-busting drugs.
Ryazan, Ryazan OblastAges 18 years+ - NCT05372718RecruitingPhase 3
Clot-busting drug versus surgery for sudden blocked leg arteries
This trial compares a clot-busting medicine (staphylokinase) against surgery in people with sudden, dangerous reduced blood flow to a leg. It may help find a safer or more effective way to restore circulation and prevent limb complications.
Kursk, Kursl RegionAges 18 years+ - NCT06362746RecruitingPhase 3
Staphylokinase for intermediate high-risk pulmonary embolism
This trial tests a new drug, staphylokinase, to see if it can break up blood clots in the lungs in people with a moderate-high risk pulmonary embolism. The goal is to improve blood flow and reduce the chance of complications.
Barnaul, Altayskiy KrayAges 18 years+ - NCT07505030Enrolling by invitationPhase 1
Safety study of LYNC-101 in healthy adults
This trial tests a new medicine called LYNC-101 in healthy volunteers to see if it is safe and how the body processes it. If you are a generally healthy adult between 18 and 60, you may be able to help researchers learn about this potential treatment.
Adelaide, South AustraliaAges 3 weeks–2 months - NCT06687369RecruitingPhase 3
Comparing a potential biosimilar to Keytruda for advanced lung cancer
This trial tests if a new drug, MB12, works as well as Keytruda for people with advanced non-small cell lung cancer who haven't had treatment yet. It aims to offer a more affordable option.
YerevanAges 18 years+ - NCT07287982RecruitingPhase 2
ARGX-119 for children with SMA who can walk
This study tests a new medicine called ARGX-119 in children with SMA. It is given through an IV and aims to help kids who can already walk get stronger and stay healthy.
Little Rock, ArkansasAges 5–17 - NCT07614776RecruitingPhase 3
New Eye Injection Treatment for Age-Related Macular Degeneration
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
Fullerton, CaliforniaAges 50 years+ - NCT07777484RecruitingPhase 1
Study of TRB-001 vaccine for Parkinson's disease after prior immunotherapy
This study tests an experimental vaccine called TRB-001 in people with Parkinson's disease who have already received a previous immunotherapy targeting alpha-synuclein. The goal is to see if the vaccine is safe and how it affects the immune system and the disease.
ViennaAges 18 years+ - NCT07764237RecruitingPhase 1
mRNA vaccine for older adults to prevent RSV and hMPV
This trial tests a new mRNA vaccine designed to protect older adults against two common respiratory viruses, RSV and hMPV. It aims to see if the vaccine is safe and creates a good immune response.
Québec, QuebecAges 60 years+ - NCT07769983Enrolling by invitationPhase 1
HIV vaccine study for people on effective treatment
This study tests a new vaccine designed to help your immune system fight HIV better. It is for people with HIV who are already on effective antiretroviral therapy and have a well-controlled virus. The goal is to see if the vaccine is safe and boosts your body's natural defenses.
Bern, Canton of BernAges 18 years+ - NCT06863142RecruitingPhase 1
Testing a new flu vaccine with or without adjuvant
This study tests a new investigational flu vaccine (FluMos-v2) with or without an adjuvant (ALFQ) to see how safe, tolerable, and effective it is. It may help protect against multiple flu strains.
Bethesda, MarylandAges 18–50 - NCT07758972RecruitingPhase 1
Gonorrhea vaccine safety study
This trial tests a new vaccine designed to protect against gonorrhea, a common sexually transmitted infection. The study checks how safe the vaccine is and how well it trains the immune system to fight the bacteria.
Neu-Ulm, BavariaAges 18–50 - NCT07737717RecruitingPhase 1
Testing an mRNA Ebola-Bundibugyo vaccine in healthy adults
This study tests a new mRNA vaccine (mRNA-1469) to prevent Ebola-Bundibugyo virus disease. It is for healthy adults to see if the vaccine is safe and produces an immune response.
Halifax, Nova ScotiaAges 18–65 - NCT07085702RecruitingPhase 1
Testing a new Strep A vaccine in healthy young adults
This study tests a new vaccine designed to protect against Group A Strep bacteria. It will check how safe the vaccine is and how well it boosts your immune system. Healthy young adults between 18 and 25 years old may be eligible.
Botany, New South WalesAges 18–25 - NCT07755436RecruitingPhase 1
Study of ARR-002 for advanced ovarian or endometrial cancer
This study tests an experimental drug called ARR-002 in people with advanced or metastatic ovarian, primary peritoneal, or fallopian tube cancer that has stopped responding to standard treatments. The goal is to see if it is safe and whether it shrinks tumors.
Irving, TexasAges 18 years+ - NCT06262776Recruiting
Shingles vaccine safety study for transplant recipients
This trial tests whether the shingles vaccine (RZV) is safe and works well for organ transplant recipients and their household members. It also includes people on dialysis or certain immunosuppressants.
Adelaide, South AustraliaAges 18 years+ - NCT04808505RecruitingPhase 3
Study of enzyme therapy for children with infant-onset Pompe disease
This trial tests how well a new enzyme treatment (cipaglucosidase alfa with miglustat) works and how safe it is in children and babies with infant-onset Pompe disease. It may help by improving muscle function after earlier treatment or, for some babies, starting treatment when no prior enzyme therapy has been given.
Gainesville, FloridaAges Up to 17 years - NCT05823285RecruitingPhase 1
Study of QLS31903 for advanced solid tumors
This Phase 1 trial tests the safety and how the medicine works in the body, and also looks at early signs of effectiveness. It is for adults with advanced solid tumors, and for Phase 1b specifically, the tumor must show a marker called GPC3.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07136389RecruitingPhase 1
Testing 2 drugs for active lupus skin disease
This trial tests two new drugs, BCD-256-1 and divozilimab, for people with systemic lupus erythematosus (SLE) who have active skin symptoms not controlled by current treatments. The goal is to see if they are safe and how the body processes them.
Saint PetersburgAges 18–70 - NCT06754605RecruitingPhase 1/Phase 2
Testing a new RSV vaccine for safety and immune response
This trial tests a new RSV vaccine in two phases. First, it will be given to healthy adults 18 and older to check safety. Then, it will be studied in adults 50 and older, including those with stable health conditions, to see if it helps protect against RSV, a common virus that can cause serious breathing problems in older people.
Langfang, HebeiAges 18–120 - NCT07636525Recruiting
Sleep and Teen Vaccine Response Study
This study looks at how sleep affects how well a meningococcal vaccine works in 11–12 year olds. Researchers want to understand if getting good sleep helps your body respond better to vaccines.
Cincinnati, OhioAges 11–12
Hear when a new Immunogenicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunogenicity?
- Yes. Clin2 currently lists 150 recruiting immunogenicity studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunogenicity trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunogenicity trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.